← Back to Search

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

N/A
Recruiting
Led By Dean E Brenner, M.D.
Research Sponsored by University of Michigan Rogel Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 day of biospecimen collection
Awards & highlights
No Placebo-Only Group

Summary

Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.

Eligible Conditions
  • Colon Cancer
  • Colorectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 day of biospecimen collection
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 day of biospecimen collection for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Biospecimen Retention: Samples with DNA

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

University of Michigan Rogel Cancer CenterLead Sponsor
300 Previous Clinical Trials
20,035 Total Patients Enrolled
Early Detection Research NetworkNETWORK
3 Previous Clinical Trials
16,255 Total Patients Enrolled
Clinical Genomics PathologyIndustry Sponsor
2 Previous Clinical Trials
553 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,111,380 Total Patients Enrolled
Great Lakes New England Clinical Validation CenterUNKNOWN
VolitionRxUNKNOWN
Department of Health and Human ServicesFED
232 Previous Clinical Trials
934,727 Total Patients Enrolled
Dean E Brenner, M.D.Principal InvestigatorUniversity of Michigan
1 Previous Clinical Trials
13,000 Total Patients Enrolled
~447 spots leftby Mar 2028